Corcept Therapeutics (CORT) 6.01 $CORT Zacks.com

New Post Public Reply Private Reply Replies (0) Message Board

Jul 10, 2016 at 5:21 PM

Corcept Therapeutics (CORT) 6.01 $CORT

Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 8:30AM CDT
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
LXP: 10.23 (+0.24), HL: 6.05 (+0.39), ARCO: 4.89 (+0.03), CORT: 6.01 (+0.14), EXEL: 8.15 (+0.01)

Explosive Stocks Under $10
Kevin Matras - ZACKS - Tue Jun 28, 2:27PM CDT
Explosive Stocks Under $10
LXP: 10.23 (+0.24), HL: 6.05 (+0.39), ARCO: 4.89 (+0.03), CORT: 6.01 (+0.14), EXEL: 8.15 (+0.01)

Corcept (CORT) Reports Early Breast Cancer Data on Korlym
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 4:06PM CDT
Corcept (CORT) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
PFE: 36.12 (+0.35), BMY: 75.28 (+1.20), CORT: 6.01 (+0.14), CELG: 105.03 (+0.62)

Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
Marketwired - Thu Jun 02, 3:05PM CDT
MENLO PARK, CA--(Marketwired - Jun 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 6.01 (+0.14)

Corcept beats 1Q profit forecasts
Automated Insights - Tue May 03, 3:35PM CDT
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $19,000 in its first quarter.
CORT: 6.01 (+0.14)

Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
Marketwired - Tue May 03, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 6.01 (+0.14)

Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
Marketwired - Fri Apr 29, 7:30AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2016. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 6.01 (+0.14)

Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers
Marketwired - Thu Apr 28, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today released data supporting the clinical advancement of its proprietary, selective cortisol modulator, CORT125134. The company has begun recruiting patients for a Phase 1/2 trial of the compound to treat patients with solid-tumor cancers. It also expects to begin recruiting patients for a Phase 2 study of CORT125134 to treat patients with Cushing's syndrome this quarter.
CORT: 6.01 (+0.14)

Corcept Therapeutics (CORT) Jumps: Stock Moves Up 9.6%
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 7:15AM CDT
Corcept Therapeutics Incorporated (CORT) shares rose almost 10% in the last trading session.
CALA: 3.63 (+0.02), CORT: 6.01 (+0.14)

Valeant CEO Gets Subpoena from Senate Aging Committee
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:45PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) dropped 7.2% after the company's CEO received a subpoena from the Senate Aging Committee amid the ongoing mess.
VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), CORT: 6.01 (+0.14)

Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:25PM CDT
Aerie Pharmaceuticals, Inc. (AERI) announced the initiation of dosing in the second phase III registration trial, Mercury 2, on its pipeline candidate, Roclatan 0.02%/0.005%.
SCMP: 11.49 (+0.10), AERI: 17.61 (+0.07), CORT: 6.01 (+0.14)

The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
SYN: 1.89 (+0.04), GERN: 2.72 (+0.03), EPZM: 10.31 (+0.39), CORT: 6.01 (+0.14)

Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 7:15AM CDT
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 8% in the last trading session.
GLMD: 4.45 (+0.10), CORT: 6.01 (+0.14)

4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 122.85 (+0.34), VRX: 23.25 (-0.24), SYN: 1.89 (+0.04), GERN: 2.72 (+0.03), AMGN: 161.10 (+4.51), EPZM: 10.31 (+0.39), CORT: 6.01 (+0.14)

Roche Files for FDA Approval of Elecsys BRAHMS Assay
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:30AM CDT
Roche Holdings, Inc. (RHHBY) announced that the company has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) with the FDA
ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), CORT: 6.01 (+0.14)

Can The Uptrend Continue for Corcept Therapeutics (CORT)?
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 9:18AM CDT
Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance
CORT: 6.01 (+0.14)

Valeant to Get a New CEO Amid Turmoil, Ackman on Board
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 11:40AM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) current chief executive officer (CEO) J. Michael Pearson has recently decided to step down.
VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), CORT: 6.01 (+0.14)

Valeant Pharmaceuticals (VRX) Jumps: Stock Adds 7.4%
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 7:00AM CDT
Valeant (VRX) was a big mover last session, with its shares rising over 7% on the day.
VRX: 23.25 (-0.24), CORT: 6.01 (+0.14)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Lunit, Summit Tackle Tumor Analysis with AI Platform

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...

Honeywell Aerospace Faces Class Action: Deadline Looms

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Millrose Faces Securities Fraud Suit Amidst Decline

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

CapCut's AI Tools Reshape Video Content Creation

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

TORRAS Stands Tall with iPhone 18 Pro Cases

By Riley Hayes Updated Oct 24, 2026 Category News Views 161

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...